See more : Jeudan A/S (JDAN.CO) Income Statement Analysis – Financial Results
Complete financial analysis of ZIVO Bioscience, Inc. (ZIVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZIVO Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ASX Limited (ASXFF) Income Statement Analysis – Financial Results
- Jiangxi GETO New Materials Corporation Limited (300986.SZ) Income Statement Analysis – Financial Results
- NEP Realty and Industry Public Company Limited (NEP.BK) Income Statement Analysis – Financial Results
- Ta Tun Electric Wire & Cable Co., Ltd. (1623.TWO) Income Statement Analysis – Financial Results
- Crown Confectionery Co., Ltd. (26490K.KS) Income Statement Analysis – Financial Results
ZIVO Bioscience, Inc. (ZIVO)
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.65K | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.89K | 82.73K | 79.14K | 176.90K | 161.34K | 297.30K | 95.97K | 49.06K | 1.68K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 16.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 138.25K | 51.81K | 63.69K | 130.04K | 167.92K | 252.88K | 191.66K | 75.28K | 1.86K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 11.61K | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -34.36K | 30.92K | 15.45K | 46.87K | -6.58K | 44.42K | -95.70K | -26.23K | -183.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 41.99% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33.07% | 37.37% | 19.52% | 26.49% | -4.08% | 14.94% | -99.72% | -53.46% | -10.89% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.38M | 2.24M | 2.12M | 3.75M | 2.31M | 2.81M | 2.38M | 788.97K | 1.03M | 1.97M | 1.02M | 677.49K | 377.89K | 395.57K | 339.32K | 148.83K | 323.19K | 333.28K | 118.11K | 192.37K | 55.71K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.90M | 6.49M | 6.93M | 4.82M | 6.05M | 3.32M | 3.95M | 2.70M | 2.02M | 1.59M | 2.09M | 1.40M | 1.51M | 3.60M | 2.10M | 898.90K | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 198.63K | 0.00 | 0.00 | 13.73K | 96.79K | 225.13K | 209.19K | 159.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.90M | 6.49M | 6.93M | 4.82M | 6.05M | 3.32M | 3.95M | 2.70M | 2.02M | 1.79M | 2.09M | 1.40M | 1.53M | 3.70M | 2.33M | 1.11M | 1.90M | 3.55M | 2.97M | 3.62M | 484.93K | 3.43K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 652.50K | 0.00 | 0.00 | -582.00 | 0.00 | 15.00K | 0.00 | 0.00 | 2.06K | 3.61K |
| Operating Expenses | 7.27M | 8.73M | 9.05M | 8.58M | 8.35M | 6.13M | 6.33M | 3.49M | 3.06M | 3.76M | 3.11M | 2.08M | 1.90M | 4.09M | 2.67M | 1.26M | 2.23M | 3.88M | 3.08M | 3.83M | 540.63K | 3.43K | 2.06K | 3.61K |
| Cost & Expenses | 7.29M | 8.73M | 9.05M | 8.58M | 8.35M | 6.13M | 6.33M | 3.49M | 3.06M | 3.76M | 3.11M | 2.08M | 2.04M | 4.14M | 2.73M | 1.39M | 2.40M | 4.14M | 3.28M | 3.91M | 542.50K | 3.43K | 2.06K | 3.61K |
| Interest Income | 0.00 | 13.32K | 233.28K | 550.05K | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.24K | 6.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 514.17K | 13.32K | 233.28K | 550.05K | 3.16M | 8.10M | 1.83M | 986.19K | 720.71K | 589.57K | 4.49M | 896.97K | 47.11K | 13.96K | 5.75K | 9.34K | 38.94K | 73.51K | 77.62K | 1.31K | 0.00 | -3.43K | -2.06K | -3.61K |
| Depreciation & Amortization | 0.00 | 4.00 | -407.49K | 8.56M | 8.35M | 18.75K | 18.75K | 25.00K | 25.00K | 29.84K | 25.69K | 74.81K | 92.40K | 37.53K | 99.58K | 33.54K | 112.81K | 632.00K | 448.59K | 15.53K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.26M | -8.73M | -9.05M | -550.05K | -8.35M | -6.13M | -6.33M | -3.49M | -3.06M | -5.15M | -3.11M | -2.08M | -1.94M | -4.02M | -2.62M | -1.18M | -2.12M | -3.21M | -2.73M | -3.84M | -540.82K | -3.43K | -2.06K | -3.61K |
| EBITDA Ratio | -26,267.67% | 0.00% | 0.00% | -42,778.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -294.94% | -1,179.88% | -4,796.11% | -329.03% | -1,379.45% | -1,201.57% | -63.92% | -7,831.89% | -32,191.49% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.26M | -8.73M | -9.05M | -8.56M | -8.35M | -6.13M | -6.33M | -3.49M | -3.06M | -5.15M | -3.11M | -2.08M | -1.94M | -4.06M | -2.65M | -1.21M | -2.23M | -3.84M | -3.18M | -3.86M | -540.82K | -3.43K | -2.06K | -3.61K |
| Operating Income Ratio | -26,267.67% | 0.00% | 0.00% | -42,778.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,865.71% | -4,909.09% | -3,352.50% | -684.02% | -1,385.08% | -1,291.33% | -3,313.23% | -7,863.55% | -32,191.49% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -514.17K | -13.32K | -110.76K | -550.05K | -3.16M | -8.50M | -3.71M | -2.57M | -2.73M | 5.83M | -6.99M | -1.17M | -793.30K | -3.05M | 1.24M | -594.44K | -16.31K | 365.15K | -2.67M | 0.00 | 540.82K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -7.78M | -8.75M | -9.16M | -9.11M | -11.51M | -14.64M | -10.04M | -6.06M | -5.79M | 680.81K | -10.10M | -3.25M | -3.48M | -7.11M | -1.41M | -1.80M | -2.13M | -3.47M | -5.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -28,127.25% | 0.00% | 0.00% | -45,528.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,347.55% | -8,592.94% | -1,783.05% | -1,020.05% | -1,320.78% | -1,168.51% | -6,095.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00 | 233.28K | 550.05K | 3.16M | 407.49K | 1.66M | 1.40M | 1.83M | -5.20M | 2.50M | 270.85K | 2.29M | 6.09M | -2.48M | 1.19M | -126.38K | -736.49K | 5.37M | 1.31K | 540.82K | 3.43K | 2.06K | 3.61K |
| Net Income | -7.78M | -8.75M | -9.40M | -9.66M | -14.67M | -14.64M | -10.04M | -6.06M | -5.79M | 680.81K | -10.10M | -3.25M | -2.73M | -7.12M | -1.42M | -1.81M | -2.25M | -3.54M | -5.96M | -3.86M | -540.82K | -3.43K | -2.06K | -3.61K |
| Net Income Ratio | -28,127.25% | 0.00% | 0.00% | -48,278.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,629.30% | -8,609.82% | -1,790.32% | -1,025.33% | -1,395.18% | -1,191.15% | -6,207.23% | -7,866.21% | -32,191.49% | 0.00% | 0.00% | 0.00% |
| EPS | -4.60 | -5.58 | -7.40 | -11.41 | -25.47 | -44.84 | -34.60 | -21.73 | -21.22 | 1.79 | -43.20 | -15.38 | -2.26 | -6.54 | -1.54 | -2.77 | -4.25 | -8.26 | -26.13 | -27.12 | -4.49 | -0.18 | -0.22 | -0.39 |
| EPS Diluted | -4.60 | -5.57 | -7.39 | -11.41 | -25.47 | -44.84 | -34.60 | -21.73 | -21.22 | 1.79 | -43.19 | -15.38 | -2.26 | -6.54 | -1.54 | -2.77 | -4.25 | -8.26 | -26.13 | -27.12 | -4.49 | -0.18 | -0.22 | -0.39 |
| Weighted Avg Shares Out | 1.69M | 1.57M | 1.27M | 846.21K | 575.83K | 326.41K | 290.09K | 278.84K | 272.80K | 379.59K | 233.70K | 211.25K | 1.21M | 1.09M | 920.65K | 655.39K | 529.93K | 428.93K | 227.95K | 142.31K | 120.34K | 18.56K | 9.28K | 9.28K |
| Weighted Avg Shares Out (Dil) | 1.69M | 1.57M | 1.27M | 846.21K | 575.83K | 326.41K | 290.09K | 278.84K | 272.80K | 379.59K | 233.78K | 211.25K | 1.21M | 1.09M | 920.65K | 655.39K | 529.93K | 428.93K | 227.95K | 142.31K | 120.34K | 18.56K | 9.28K | 9.28K |
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that...
ZIVO Bioscience Announces Uplisting to OTCQB Market
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its...
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis...
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate...
ZIVO Bioscience Announces Reverse Stock Split
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a...
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will...
Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler...
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on the commercialization of...
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the commercialization of its proprietary algal biomass...
ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on No News
ZIVO Bioscience (ZIVO) stock is rocketing higher on Friday despite no news concerning the company in what appears to be a pump and dump. The post ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on...
Source: https://incomestatements.info
Category: Stock Reports